Compare BBCP & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBCP | CTKB |
|---|---|---|
| Founded | 1983 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 356.0M | 652.1M |
| IPO Year | 2017 | 2021 |
| Metric | BBCP | CTKB |
|---|---|---|
| Price | $6.88 | $4.15 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $8.25 | $5.70 |
| AVG Volume (30 Days) | 93.1K | ★ 694.6K |
| Earning Date | 06-19-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $392,867,000.00 | $193,015,000.00 |
| Revenue This Year | $3.49 | $5.02 |
| Revenue Next Year | N/A | $7.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 17.67 |
| 52 Week Low | $5.04 | $2.37 |
| 52 Week High | $7.80 | $6.18 |
| Indicator | BBCP | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 54.34 | 39.20 |
| Support Level | $6.64 | $4.09 |
| Resistance Level | $7.28 | $4.26 |
| Average True Range (ATR) | 0.33 | 0.21 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 49.06 | 31.54 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.